The history of Pinnacle 21 Blog The history of Pinnacle 21 2025年2月21日 It was late 2007. Mad Men was the hottest show on TV.…Certara2025年2月21日
How to validate your clinical data using FDA validation rules Blog FDAのバリデーションルールを用いた臨床データのバリデーション方法 2025年1月30日 For clinical data managers, understanding clinical data validation and applying FDA validation…Certara2025年1月30日
GlobalSubmit eCTD 4.0 Webinars On-Demand Webinar GlobalSubmit eCTD 4.0 ウェビナー The world of electronic regulatory submissions is about to change with the introduction of eCTD…Certara2024年12月3日
Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi Poster Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi Certara2024年11月22日
Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis. ポスター Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis. Certara2024年11月22日
Clinical Metadata Standardization: Evaluating the Importance of a Metadata Repository in Clinical Trials White Paper Clinical Metadata Standardization: Evaluating the Importance of a Metadata Repository in Clinical Trials Whether you’re considering a metadata repository or want to learn about clinical metadata standardization, our…Certara2024年11月22日
Building Automated Pharmacometrics Analysis Workflows in R with NMsim Poster Building Automated Pharmacometrics Analysis Workflows in R with NMsim Certara2024年11月22日
Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Potential Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia Poster Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Potential Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia Certara2024年11月22日
Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites Poster Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites Certara2024年11月22日
Indirect Exposure-Response Modeling for Transthyretin Amyloid Cardiomyopathy Treated with Acoramidis (AG10) Poster Indirect Exposure-Response Modeling for Transthyretin Amyloid Cardiomyopathy Treated with Acoramidis (AG10) Certara2024年11月22日